Novo Nordisk needs something new, outside of weigh-loss drugs, says BMO's Seigerman

Key Concepts:

• Novo Nordisk stock drop
• Ozempic and Wegovy
• Semaglutide
• Eli Lilly's competitive advantage
• Compounding pharmacies
• Market share
• Guidance cut
• New CEO
• Acquisitions
• Innovation
• Volume vs. Price
• GLP-1 drugs
• Tirzepatide

Novo Nordisk's Stock Drop and Guidance Cut:

• Novo Nordisk's shares dropped 22%, marking its worst day since 1987, after the company slashed its guidance for the second time this year.
• The guidance cut is attributed to volume issues, not price reductions.
• The company's reliance on semaglutide (Ozempic, Wegovy, Rybelsus) is a key concern.
• The new CEO, Mazzy Star (an insider), was not the preferred choice of investors, who were hoping for a US-based leader or a woman.

New CEO and Strategy:

• The new CEO's focus on international markets is frustrating investors, as the US is Novo Nordisk's biggest market.
• The CEO mentioned the need to react quicker, respond more quickly, and accelerate growth, suggesting potential acquisitions.
• The company needs to bolster its pipeline beyond semaglutide, likely through acquisitions.

Compounding Pharmacies and Market Share:

• Approximately one million patients are using compounded semaglutide, posing a significant challenge to Novo Nordisk.
• Novo Nordisk has struggled to address the compounding issue effectively, unlike Eli Lilly.

Eli Lilly's Competitive Advantage:

• Eli Lilly is performing strongly, with Mounjaro eclipsing Wegovy and Ozempic in script numbers.
• Eli Lilly has invested heavily in manufacturing and direct-to-consumer (DTC) marketing.
• Eli Lilly does not have the same compounding issues as Novo Nordisk.
• Eli Lilly is expected to gain a larger share of the market.
• Eli Lilly is expected to have an oral medication on the market in a year or so.

Market Dynamics and Future Strategies:

• Novo Nordisk is losing market share rapidly.
• The valuation of these stocks is based on the belief that they will command a significant share of the market.
• Novo Nordisk needs to increase volume and re-engage with physicians who may have been frustrated by product shortages.
• Novo Nordisk needs to innovate and develop a competitor to Tirzepatide (Mounjaro).
• Novo Nordisk needs to refocus its R&D portfolio and reinvigorate its commercial business.

Acquisition Strategy:

• Novo Nordisk needs to acquire new assets to diversify its portfolio beyond semaglutide.

Volume vs. Price:

• Novo Nordisk does not want to engage in a price war, as it would erode the market's profitability.

Conclusion:

Novo Nordisk faces significant challenges, including declining market share, reliance on a single drug (semaglutide), and the rise of competitors like Eli Lilly. The company needs to innovate, acquire new assets, and improve its commercial execution to regain its competitive edge. The new CEO's strategy and ability to address these challenges will be crucial for the company's future success.